IBRX: ImmunityBio, Inc.
About
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Current Value
$5.321 Year Return
Current Value
$5.321 Year Return
Key Details
Market Cap
$3.73B
P/E Ratio
-6.03
1Y Stock Return
43.05%
1Y Revenue Growth
1218.71%
Dividend Yield
0.00%
Price to Book
-5.0
Strategies that include IBRX
Stock's related to IBRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RXRX | 35.50% | $1.80B | -4.13% | 0.00% |
| VICR | 35.09% | $2.40B | +39.81% | 0.00% |
| FOXF | 33.80% | $1.33B | -47.63% | 0.00% |
| DAWN | 33.45% | $1.36B | +13.42% | 0.00% |
| FARO | 32.68% | $486.17M | +40.51% | 0.00% |
| ROG | 32.42% | $1.88B | -23.03% | 0.00% |
| KRYS | 32.36% | $5.12B | +75.65% | 0.00% |
| FUN | 31.65% | $4.60B | -16.51% | 0.00% |
| OCUL | 31.49% | $1.40B | +307.31% | 0.00% |
| NMRK | 31.17% | $2.60B | +94.74% | 0.79% |
| NNE | 30.82% | $833.66M | +531.50% | 0.00% |
| KTOS | 30.71% | $3.78B | +33.46% | 0.00% |
| ALEX | 30.57% | $1.41B | +18.14% | 4.59% |
| APAM | 30.26% | $3.25B | +26.70% | 6.08% |
| ASTH | 29.68% | $2.01B | +24.82% | 0.00% |
| SEG | 29.23% | $319.72M | +12.41% | 0.00% |
| SNDX | 29.23% | $1.35B | +2.87% | 0.00% |
| NGVT | 29.23% | $1.67B | +18.26% | 0.00% |
| PLL | 29.01% | $238.11M | -56.47% | 0.00% |
| TTMI | 28.94% | $2.38B | +65.25% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRVO | -0.04% | $83.20M | +2.86% | 0.00% |
| SEM | 0.05% | $4.79B | +59.80% | 1.35% |
| FCFS | 0.05% | $4.70B | -6.20% | 1.39% |
| CVE | 0.12% | $29.32B | -10.19% | 2.95% |
| FANG | 0.13% | $52.59B | +18.15% | 2.79% |
| ALL | 0.18% | $52.06B | +45.67% | 1.85% |
| WEX | 0.21% | $7.10B | +2.88% | 0.00% |
| IMNN | -0.22% | $10.02M | -22.89% | 0.00% |
| SHEN | 0.24% | $698.36M | -44.66% | 0.79% |
| LKQ | 0.24% | $9.77B | -17.44% | 3.20% |
| K | -0.27% | $27.77B | +52.50% | 2.79% |
| DUK | -0.28% | $87.74B | +26.37% | 3.65% |
| SSNC | -0.31% | $18.06B | +32.62% | 1.33% |
| MO | 0.33% | $94.67B | +37.05% | 7.07% |
| KR | -0.34% | $42.03B | +35.08% | 2.11% |
| KVUE | 0.34% | $45.42B | +19.05% | 3.43% |
| CAG | 0.35% | $12.64B | -6.10% | 5.26% |
| CWST | -0.42% | $6.92B | +36.68% | 0.00% |
| X | 0.45% | $8.76B | +13.32% | 0.51% |
| REYN | 0.46% | $5.79B | +3.76% | 3.35% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TNET | -20.27% | $4.41B | -19.81% | 0.84% |
| WHLM | -18.98% | $17.64M | -29.34% | 0.00% |
| WKC | -17.64% | $1.61B | +30.46% | 2.33% |
| UVE | -16.80% | $631.63M | +36.40% | 2.86% |
| KNSL | -15.98% | $10.93B | +29.38% | 0.13% |
| CPRI | -13.90% | $2.36B | -58.95% | 0.00% |
| AON | -12.15% | $82.00B | +16.33% | 0.70% |
| PRT | -11.89% | $48.72M | -16.56% | 10.33% |
| HIHO | -10.98% | $8.63M | 0.00% | 6.12% |
| PULM | -10.81% | $19.83M | +202.98% | 0.00% |
| SCKT | -10.62% | $10.88M | +15.32% | 0.00% |
| RNR | -10.37% | $13.74B | +23.09% | 0.58% |
| HIG | -9.49% | $33.87B | +51.09% | 1.60% |
| ACGL | -9.33% | $36.00B | +16.84% | 0.00% |
| CBOE | -9.30% | $21.46B | +15.84% | 1.11% |
| CHKP | -9.16% | $19.20B | +20.74% | 0.00% |
| SNY | -9.11% | $120.34B | +3.11% | 4.25% |
| UNM | -8.76% | $13.16B | +69.20% | 2.16% |
| MCK | -8.67% | $78.15B | +35.51% | 0.42% |
| ATNI | -8.41% | $290.80M | -37.65% | 4.95% |
ETF's related to IBRX
News
Yahoo
Over the last 7 days, the United States market has dropped 1.2%, yet it remains up by 30% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of robust annual growth and recent volatility, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on future earnings potential.
Yahoo
CULVER CITY, Calif., November 19, 2024--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) have been treated with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with BCG, achieving a 71% complete response (CR) rate. In these responders, the range
Finnhub
SAN FRANCISCO, Nov. 19, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises ImmunityBio, Inc. investors that the firm is investigating potential legal claims relating to the company's...
Finnhub
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a...
Yahoo
CULVER CITY, Calif., November 12, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024.
Finnhub
SAN DIEGO — SAN DIEGO — ImmunityBio, Inc. on Tuesday reported a loss of $85.7 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 14 cents. ...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.